European Pharmaceutical Review

JULY 13, 2023

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).

Medical 85

Medical Food and Drug Administration Pharmacology Medicine 85

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 77

Food and Drug Administration Safety Patients Leads 77

Pharmaceutical Technology

FEBRUARY 13, 2023

Key considerations in the candidate selection stage The first step in a drug development program is choosing the optimum molecule from a range of potential leads that have been optimized within drug discovery. We start by using in-silico modeling of any pre-existing data associated with the lead compounds.

Food and Drug Administration 52

Food and Drug Administration Leads Pharmaceutical Pharmaceutical research 52

Pharmaceutical Technology

AUGUST 8, 2022

In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. These days, he is leading trials involving a system developed by the digital health company etectRx (pronounced as e-tect-are-ex), which works with investigators who can use such real-time data.

Food and Drug Administration 122

Food and Drug Administration FDA Medicine Patients 122